Avinger, Inc. (NASDAQ:AVGR) manufacturer of medical devices and components, is reporting third quarter earnings results on Tuesday 10th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.1 per share.
For the full year, analysts predict revenues of $ 8.04 million, while looking forward to loss of $ 0.69 per share.
Previous Quarter Performance
Avinger, Inc. communicated loss for the second quarter of $ 0.18 per share, from the revenue of $ 1.50 million. The quarterly revenues contracted 35.34 percent compared with the same quarter last year. Street analysts expected Avinger, Inc. to report loss of $ 0.20 per share on revenue of $ 1.34 million for the second quarter. The bottom line results beat street analysts by $ 0.02 or 10.00 percent, at the same time, top line results outshined analysts by $ 0.16 million or 11.94 percent.
Stock Performance
Shares of Avinger, Inc. traded up $ 0.01 or 4.70 percent on Monday, reaching $ 0.26 with volume of 2.76 million shares. Avinger, Inc. has traded high as $ 0.28 and has cracked $ 0.25 on the downward trend
According to the previous trading day, closing price of $ 0.26, representing a 19.05 % increase from the 52 week low of $ 0.21 and a 84.66 % decrease over the 52 week high of $ 1.63.
The company has a market capital of $ 21.96 million and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 16th September 2020, maintained by Aegis at Buy rating, with $ 1.00 target price.
Conference Call
Avinger, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.avinger.com
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The companys lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.
